Introduction: E. faecium and E. faecalis are responsible for 13.9% of hospital-acquired infections with frequent resistance to vancomycin (82.6% of E. faecium, 9.5% of E. faecalis). Medical device infections secondary to enterococci often require combination therapy due to impaired activity against biofilm embedded cells. In vitro data demonstrate synergistic activity of daptomycin combinations. Using a novel, biofilm time-kill approach, we evaluated whether daptomycin combinations maintained synergy against biofilm-producing E. faecium and E. faecalis. Methods: Broth microdilution (BMD) and biofilm MIC (bMIC) values for daptomycin, ampicillin, ceftriaxone, fosfomycin, and rifampin were determined against biofilm-producing E. faecium and E....
For enterococcal implant-associated infections, the optimal treatment regimen has not been defined. ...
Enterococcus faecalis (E. faecalis) has become a major leading cause of nosocomial endocarditis. Tre...
Enterococci that are nonsusceptible (NS; MIC > 4 μg/ml) to daptomycin are an emerging clinical co...
Abstract Introduction Enterococcus faecalis is a significant cause of nosocomial infections and is d...
The widespread incidence of enterococci resistant to ampicillin, vancomycin and aminoglycosides, the...
Enterococci are the thirdmost frequent cause of infective endocarditis. A high-inoculum stationary-p...
Objectives: To assess the in vitro antibiotic susceptibility of Enterococcus faecalis in biofilms. M...
Enterococci are the third most frequent cause of infective endocarditis. A high-inoculum stationary-...
Multidrug-resistant (MDR) Enterococcus faecium is a challenging pathogen known to cause biofilm-medi...
ObjectivesTo assess the in vitro antibiotic susceptibility of Enterococcus faecalis in biofilms.Meth...
In this study, we have evaluated the effects of previously characterized bacteriocins produced by E....
Biofilms are associated with persistence of Staphylococcus aureus infections and therapeutic failure...
Enterococcus faecalis is increasingly found as the causative organism of infective endocarditis, an ...
Biofilm-related infections remain a scourge. In an in vitro model of biofilms using Staphylococcus a...
Biofilm-related infections remain a scourge. In an in vitro model of biofilms using Staphylococcus a...
For enterococcal implant-associated infections, the optimal treatment regimen has not been defined. ...
Enterococcus faecalis (E. faecalis) has become a major leading cause of nosocomial endocarditis. Tre...
Enterococci that are nonsusceptible (NS; MIC > 4 μg/ml) to daptomycin are an emerging clinical co...
Abstract Introduction Enterococcus faecalis is a significant cause of nosocomial infections and is d...
The widespread incidence of enterococci resistant to ampicillin, vancomycin and aminoglycosides, the...
Enterococci are the thirdmost frequent cause of infective endocarditis. A high-inoculum stationary-p...
Objectives: To assess the in vitro antibiotic susceptibility of Enterococcus faecalis in biofilms. M...
Enterococci are the third most frequent cause of infective endocarditis. A high-inoculum stationary-...
Multidrug-resistant (MDR) Enterococcus faecium is a challenging pathogen known to cause biofilm-medi...
ObjectivesTo assess the in vitro antibiotic susceptibility of Enterococcus faecalis in biofilms.Meth...
In this study, we have evaluated the effects of previously characterized bacteriocins produced by E....
Biofilms are associated with persistence of Staphylococcus aureus infections and therapeutic failure...
Enterococcus faecalis is increasingly found as the causative organism of infective endocarditis, an ...
Biofilm-related infections remain a scourge. In an in vitro model of biofilms using Staphylococcus a...
Biofilm-related infections remain a scourge. In an in vitro model of biofilms using Staphylococcus a...
For enterococcal implant-associated infections, the optimal treatment regimen has not been defined. ...
Enterococcus faecalis (E. faecalis) has become a major leading cause of nosocomial endocarditis. Tre...
Enterococci that are nonsusceptible (NS; MIC > 4 μg/ml) to daptomycin are an emerging clinical co...